As of Aug 28
| +4.17 / +3.98%|
The 12 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 144.50, with a high estimate of 180.00 and a low estimate of 108.00. The median estimate represents a +32.48% increase from the last price of 109.07.
The current consensus among 14 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.